Dr. Maughan Discusses Abiraterone Plus Olaparib in mCRPC

Video

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses the combination of abiraterone acetate (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer.

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses the combination of abiraterone acetate (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC).

The combination of the antiandrogen agent abiraterone and the PARP inhibitor olaparib demonstrated a 35% reduction in the risk of disease progression or death compared with abiraterone alone in pretreated patients with mCRPC. Findings presented at the 2018 ASCO Annual Meeting demonstrated a median progression-free survival of 13.8 months with the combination compared with 8.2 months with single-agent abiraterone (HR, 0.65; 95% CI, 0.44-0.97; P = .034).

Maughan says that although these are positive results, another study of abiraterone plus a PARP inhibitor—veliparib—showed a benefit only in biomarker-positive patients. This makes interpreting the results with abiraterone plus olaparib a challenge, he adds, as some of the data are contradictory. More details on the different patient populations needs to be released after further investigation is completed.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH